{"id":"omt-strategy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL263010","moleculeType":"Protein","molecularWeight":"1220.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OMT strategy is not a single drug but rather a clinical protocol that combines evidence-based medications (typically including antiplatelet agents, beta-blockers, ACE inhibitors, and statins) to optimize outcomes in cardiovascular patients. This multi-drug approach targets multiple pathways involved in atherosclerosis, thrombosis, and cardiac dysfunction to reduce morbidity and mortality.","oneSentence":"OMT strategy refers to Optimal Medical Therapy, a comprehensive treatment approach combining multiple pharmacological agents to manage cardiovascular disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:17.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome management"},{"name":"Chronic coronary artery disease"},{"name":"Post-myocardial infarction secondary prevention"}]},"trialDetails":[{"nctId":"NCT05824520","phase":"NA","title":"Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-10-10","conditions":"Coronary Artery Disease, Myocardial Ischaemia","enrollment":1066},{"nctId":"NCT06855537","phase":"PHASE4","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-03","conditions":"Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma","enrollment":2190},{"nctId":"NCT05860205","phase":"NA","title":"A Multiple Component Mobile-aid Pain Reduction Intervention to Decrease Myofascial Pain","status":"UNKNOWN","sponsor":"Kailea Manning","startDate":"2023-05","conditions":"Myofascial Pain Syndrome","enrollment":30},{"nctId":"NCT01985360","phase":"PHASE4","title":"ISCHEMIA-Chronic Kidney Disease Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01","conditions":"Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases","enrollment":777},{"nctId":"NCT05037695","phase":"PHASE4","title":"SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-07-21","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease, Acute Kidney Injury","enrollment":40},{"nctId":"NCT04808661","phase":"NA","title":"EndovaScular Versus mediCaL mAnagement of Uncomplicated Type B Intramural heMatoma Trial (ESCLAIM)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-03-01","conditions":"Intramural Hematoma","enrollment":154},{"nctId":"NCT03970395","phase":"NA","title":"Effectiveness of Osteopathic Manipulative Therapy in Nonsynostotic Plagiocephaly","status":"COMPLETED","sponsor":"PRIOLO CLAUDIO","startDate":"2016-09-01","conditions":"Nonsynostotic Plagiocephaly","enrollment":96},{"nctId":"NCT04127617","phase":"NA","title":"Effects of Osteopathic Manipulative Treatment in People With Neurogenic Bowel Dysfunction","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2019-10-28","conditions":"Central Nervous System Injury, Neurogenic Bowel Dysfunction","enrollment":70},{"nctId":"NCT03300011","phase":"NA","title":"Ultrasonic Cardiogram Evaluate the Prognosis of Percutaneous Revascularization of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Southeast University, China","startDate":"2016-10-01","conditions":"Coronary Chronic Total Occlusion","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"OMT strategy","genericName":"OMT strategy","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OMT (Optimal Medical Therapy) strategy is a comprehensive treatment approach that combines multiple pharmacological and lifestyle interventions to optimize cardiovascular outcomes. Used for Cardiovascular disease management and risk reduction, Coronary artery disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}